Oncoleader | Videos | Don’t Underestimate This NK Cell Engager From Innate Pharma
Video Description
About 85% of cancer immunotherapies, such as cancer vaccines, checkpoint inhibitors, and CAR-T cells, target T cell biology due to their potent cytotoxic abilities. However, T cell therapies often cause significant toxicities. Natural killer (NK) cells present a safer alternative but lack the expansive power of T cells, limiting their therapeutic potential. Innate Pharma has developed an NK cell engager that may overcome this limitation, unlocking NK cell therapy for cancer treatment.
Link to Innate Pharma Science Immunology publication: https://www.science.org/doi/10.1126/sciimmunol.adp3720
Original video release date: November 19th, 2024
Video Host
Jeff Martin, PhD
Dr. Jeff Martin is a cancer biologist with a PhD in Cancer Genetics and over a decade of experience in immuno-oncology. As the Founder of Oncoleader, Jeff currently advises biotech professionals, providing expert insights on the best ways to navigate the current trends in the immuno-oncology industry.
